Cystiflash
Food supplement declared in France, declaration No 2017-1-845
Cystiflash (Aragan) is a food supplement declared in France. Status: earlier declaration, replaced by the 2023 declaration. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- Aragan
- Food business operator placing the product on the market
- ARAGAN
- Status
- Earlier declaration, replaced by the 2023 declaration : Cystiflash
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Directions for use
- Prendre une gélule le matin et une le soir
- Not recommended (according to the manufacturer)
- Breastfeeding women, Young children (aged 1 to 3), Pregnant women
- Objectives stated by the manufacturer (these are not authorised claims)
- Urinary system
Declaration 266407, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Erica cinerea L. | Sommités fleuries | Extrait sec aqueux | 335 mg |
| Vaccinium macrocarpon Aiton | Fruit | Poudre (de plantes séchées ou broyées) | 295 mg |
| Citrus limon (L.) Burm. f. | Huile essentielle | Pression à froid | 15 mg |
| Origanum vulgare L. | Huile essentielle (fleur) | Distillation | 15 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Dioxyde de silicium | Silicium | pas de limite (données insuffisantes) | no fixed dose |
Additives
E470b, Hydroxypropyl Méthyl Cellulose
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
RÉCAUTIONS D'UTILISATION Ne pas dépasser la dose journalière recommandée. À conserver de préférence au frais. Tenir hors de portée des jeunes enfants. Ce complément alimentaire ne se substitue pas à une alimentation variée et équilibrée ni à un mode de vie sain. Ce produit est déconseillé aux enfants de moins de 6 ans, aux femmes enceintes ou allaitantes. Les personnes sous contrôle médical doivent demander conseil à leur pharmacien ou à leur médecin. Ne convient pas aux personnes allergiques à l'un des constituants.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vaccinium macrocarpon Aiton
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Cystiflash Aragan, declared in 2023 : different composition: 5 ingredient(s) added, 4 missing
- Cystiflash Aragan, declared in 2022, earlier declaration, replaced by the 2023 declaration : different composition: 4 ingredient(s) added, 3 missing
- CYSTIFLASH ARAGAN, declared in 2019, earlier declaration, replaced by the 2023 declaration : different composition: 1 ingredient(s) added, 3 missing
Brand : Aragan
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.